Avidity Biosciences Unveils 2024 Growth Agenda and Milestones

In 2024, Avidity Biosciences, a biopharmaceutical firm specializing in RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), has outlined a strategic roadmap for growth and development. The company is set to launch the Phase 3 HARBOR™ clinical trial for AOC 1001, a treatment for myotonic dystrophy type 1 (DM1), in mid-2024. This decision follows positive results from the Phase 1/2 MARINA® trial and the MARINA-OLE™ open-label extension study, which showed significant improvements in myotonia, muscle strength, mobility, and safety for DM1 patients.
Avidity also intends to release data throughout 2024 from its three clinical programs focused on rare muscle diseases: DM1, Duchenne muscular dystrophy with exon 44 skipping mutations (DMD44), and facioscapulohumeral muscular dystrophy (FSHD). The company will escalate the dosage for remaining participants in the MARINA-OLE trial and push forward its cardiology programs, building on a recent collaboration expansion with Bristol Myers Squibb. With a solid financial foundation projected to last through 2025, Avidity is well-positioned to execute its plans.
Sarah Boyce, Avidity's CEO, emphasized the company's commitment to leveraging its DM1 and DMD44 programs' data while advancing research and development initiatives. She also welcomed Eric B. Mosbrooker as the new Chief Strategy Officer, highlighting his extensive experience in global commercial operations and his strategic acumen, which will be instrumental as Avidity transitions into a global entity.
Mosbrooker, with over two decades of experience, has a background in gene therapy and rare diseases, having previously held leadership roles at Cognoa, Audentes Therapeutics, and Horizon Pharmaceuticals. He expressed his enthusiasm for joining Avidity and contributing to the company's mission of transforming lives through targeted RNA therapeutics.
Avidity's mission is to enhance lives through its innovative AOC platform, which has already achieved the targeted delivery of RNA into muscle tissue. The company is at the forefront of clinical development for DM1, DMD, and FSHD and is expanding its pipeline into cardiology and immunology through internal research and strategic partnerships. Headquartered in San Diego, CA, Avidity continues to innovate in the RNA therapeutics space, aiming to treat a wide range of diseases beyond its current focus on rare muscle conditions.